News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Recently, antimicrobial resistance has re-emerged in the public limelight as an increasingly severe global health problem.
Some of the best medicines happen by accident. Will someone one day write the same of Novartis’s branaplam in correlation with Huntington’s disease?
BMS achieved a monumental milestone when the U.S. Food and Drug Administration approved Opdualag (nivolumab and relatlimab-rmbw) for the treatment of melanoma.
The data showed mixed end results, but the diagnostics involved in treating Alzheimer’s were the star of the conference.
Learn how to successfully hire interns. Also, find some tips on how to manage and support both in-office and remote interns in our comprehensive guide.
Following her ouster as CEO of Athira Pharma, Leen Kawas has co-founded Propel Bio Partners, an equity investment firm focused on helping other life sciences companies.
It was a busy week for clinical trial announcements. Here’s a look.
Martin Shkreli will not be able to delay paying nearly $25 million he owes from a civil lawsuit that he and his company employed on Daraprim.
Merck announced that its proposed treatment Keytruda for non-small cell lung cancer delivered positive results from its Phase III trial.
With the International Conference on Alzheimer’s and Parkinson’s Diseases still ongoing, there has been increased news about Alzheimer’s. Here’s a look at just a few of the latest stories.